Semaglutide treatment in hypothalamic obesity: Two-Year outcomes on body composition, appetite, and quality of life
Authors' conclusion
Semaglutide is a safe treatment that led to long-term sustained improvements in eating behavior, weight control, and improved metabolic health. Patients reported an improved quality of life, which persisted after body weight stabilization.
Study context
- Population
- Female patients with hypothalamic obesity following craniopharyngioma treatment
- Participants
- 4 patients
- Outcome
- Weight loss
- Follow-up
- 24 months
Main finding
As reported in the abstract
Semaglutide
16%
median · 95% CI 8–34%
- Median weight loss, p = 0.004
- 16%
- Maximal weight loss at 6 months
- 17%
Observational data: associations, not effects.
Further findings
Maximal weight loss · 6 months
- Maximal weight loss
- 17%
Emotional eating score (TFEQ, range 0-100) · 24 months
- Decrease in emotional eating score: 44 units
- 44 (95% CI - 69 to - 19, p = 0.011)
Uncontrolled eating score (TFEQ, range 0-100) · 24 months
- Decrease in uncontrolled eating score: 27 units
- 27 (95% CI - 63 to 9, p = 0.097)
Fat mass (DXA) · 24 months
- Decrease in fat mass
- 10% (95% CI 2 to 44%, p = 0.016)
Lean mass (DXA) · 24 months
- Decrease in lean mass
- 19% (95% CI 14 to 26%, p < 0.001)
Bone mineral content · 24 months
- Stable bone mineral content
HbA1c · 24 months
- Decline in HbA1c
- 6.4 mmol/mol (95% CI 2.3 to 9.9, p = 0.016)
LDL-C · 24 months
- Decline in LDL-C
- 0.5 mmol/L (95% CI 0.3 to 0.7, p = 0.012)
Interviews: hunger and quality of life · 24 months
- Reduced hunger, improved self-confidence, less isolation and higher productivity
Safety
Tolerability
- Well tolerated; side effects mainly mild GI symptoms
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →